國家衛生研究院 NHRI:Item 3990099045/3055
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 857836      Online Users : 835
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/3055


    Title: Biodistribution, pharmacokinetics and microSPECT/CT imaging of Re-188-BMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model
    Authors: Chang, YJ;Chang, CH;Chang, TJ;Yu, CY;Chen, LC;Jan, ML;Luo, TY;Lee, TW;Ting, G
    Contributors: National Institute of Cancer Research
    Abstract: Nanoliposomes are useful carriers in drug delivery. Radiolabeled nanoliposomes have potential applications in radiotherapy and diagnostic imaging. In this study, the biodistribution and pharmacokinetics of Re-188-BMEDA-labelled pegylated liposomes (RBLPL) and unencapsulated Re-188-BMEDA administered by the i.v. route in murine C26-colon tumour-bearing mice were investigated. MicroSPECT/CT images were performed to evaluate the distribution and tumor targeting of RBLPL in mice. For the biodistribution study, the highest uptake of liposome in tumors was 3.62% 0.73% at 24 h after RBLPL administration, and the tumor to muscle ratio of RBLPL was 7.1-fold higher than that of 188Re-BMEDA. With image analysis, the highest SUV in tumor was 2.81 +/- 0.26 at 24 h after injection of RBLPL. The Pearson correlation analysis showed a positive correlation of tumor targeting or uptake of RBLPL between biodistribution and microSPECT semi-quantification imaging analysis (r=0.633). The results of the pharmacokinetics revealed that the area under the tissue concentration-time curve (AUC) of RBLPL was 4.7-fold higher than that of unencapsulated Re-188-BMEDA. These results suggested the potential benefit and advantage of Re-188-labeled nanoliposomes for imaging and treatment of malignant diseases.
    Keywords: Oncology
    Date: 2007-07
    Relation: Anticancer Research. 2007 Jul-Aug;27(4B):2217-2225.
    Link to: http://ar.iiarjournals.org/content/27/4B/2217.abstract
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0250-7005&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000248545900014
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=34547773740
    Appears in Collections:[Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ISI000248545900014.pdf238KbAdobe PDF327View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback